Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib
(GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma
(iNHL).
Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg
twice per day. Treatment with idelalisib can continue in compliant participants for up to
twelve 28-day cycles of idelalisib. Participants who appear to be benefiting from treatment
at the completion of 12 cycles of treatment with idelalisib may be eligible for participation
in a long-term safety extension study of idelalisib.